InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Cleo Diagnostics Ltd (ASX: COV) - Announcements

Current share price for COV : $0.290 0.005 (1.69%)+

ASX company news and announcements for Cleo Diagnostics Ltd (COV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cleo Diagnostics Ltd (COV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cleo Diagnostics Ltd (COV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cleo Diagnostics Ltd (COV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Quarterly activities and cashflow report 29 Jan 2026 8:24AM $0.765 $0.290 fallen by 62.09%
$40 Ceasing to be a substantial holder 5 Jan 2026 3:26PM $0.605 $0.290 fallen by 52.07%
$40 Chairman's End of Year Letter to Shareholders 29 Dec 2025 11:23AM $0.610 $0.290 fallen by 52.46%
$40 Cleansing Notice 29 Dec 2025 11:16AM $0.620 $0.290 fallen by 53.23%
$40 Notification regarding unquoted securities - COV 29 Dec 2025 11:11AM $0.620 $0.290 fallen by 53.23%
$40 Application for quotation of securities - COV 29 Dec 2025 11:06AM $0.635 $0.290 fallen by 54.33%
$40 Application for quotation of securities - COV 29 Dec 2025 11:04AM $0.635 $0.290 fallen by 54.33%
$40 Proposed issue of securities - COV 18 Dec 2025 9:54AM $0.685 $0.290 fallen by 57.66%
$40 CLEO Raises $5m to Support U.S. Market Launch 18 Dec 2025 9:53AM $0.685 $0.290 fallen by 57.66%
$40 Trading Halt 17 Dec 2025 8:50AM $0.685 $0.290 fallen by 57.66%
$40 Notice under Listing Rule 3.10A 28 Nov 2025 4:31PM $0.630 $0.290 fallen by 53.97%
$40 Cleo Strengthens Cash Position with $1.7m R&D Tax Refund 26 Nov 2025 8:25AM $0.635 $0.290 fallen by 54.33%
$40 Results of Annual General Meeting 24 Nov 2025 2:40PM $0.615 $0.290 fallen by 52.85%
$40 CLEO Appoints First Key Opinion Leader to Support US Market 19 Nov 2025 10:02AM $0.485 $0.290 fallen by 40.21%
$40 CLEO Significantly Expands Addressable Market 6 Nov 2025 9:19AM $0.395 $0.290 fallen by 26.58%
$40 Quarterly activities and cashflow report 31 Oct 2025 2:39PM $0.400 $0.290 fallen by 27.50%
$40 CLEO Successfully Completes Stage 1 MDSAP Audit 30 Oct 2025 9:44AM $0.425 $0.290 fallen by 31.76%
$40 Letter to Shareholders 25 Sep 2025 4:28PM $0.370 $0.290 fallen by 21.62%
$40 Notice of Annual General Meeting/Proxy Form 25 Sep 2025 4:14PM $0.370 $0.290 fallen by 21.62%
$40 Application for quotation of securities - COV 19 Sep 2025 4:33PM $0.400 $0.290 fallen by 27.50%
$40 Cleo Receives Positive FDA Feedback 15 Sep 2025 9:30AM $0.375 $0.290 fallen by 22.67%
$40 Notice Required Under ASX Listing Rule 3.13.1 5 Sep 2025 4:34PM $0.360 $0.290 fallen by 19.44%
$40 Appendix 4G and Corporate Governance Statement 26 Aug 2025 4:55PM $0.360 $0.290 fallen by 19.44%
$40 Appendix 4E and 2025 Annual Report 26 Aug 2025 4:48PM $0.360 $0.290 fallen by 19.44%
$40 COV Commences Health Economic Study-Support US Market Entry 18 Aug 2025 9:22AM $0.350 $0.290 fallen by 17.14%

26 - 50 of 151 results

Page 2 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.